© 1998 by European Society of Cardiology
Copyright © 1998, European Society of Cardiology
Prevalence of the prothrombin gene variant 20210 G
A among patients with myocardial infarction
aHematology–Hemotherapy Center, State University of Campinas, C.P. 6198, C.E.P. 13081-970, Campinas, SP Brazil
bHeart Institute, University of São Paulo, São Paulo, Brazil
* Corresponding author. Fax: +55-19-788-8750/+55-192-393511; E-mail: vrarruda@hotmail.com
Objective: The aim of this study was to determine the prevalence of the prothrombin variant allele 20210A among survivors of myocardial infarction Background: The prothrombin gene variant has been identified as a novel genetic risk factor for venous thrombosis. However, the risk of developing arterial thrombosis as a result of the presence of this mutated allele is unknown. Methods: The G
A transition at position 20210 of the 3'-untranslated region was determined in 220 survivors of myocardial infarction and in 295 individuals from the general population. Results: The prevalence of heterozygotes for the prothrombin mutated allele was 3% among patients with myocardial infarction and 0.7% in the general population (P = 0.03). No age-related difference in the prevalence of the mutated allele was observed. However, for individuals over 45 years old the prevalence among females was higher than among males (5% vs. 0%). Conclusion: These data suggest that being heterozygote for the allele variant 20210A of the prothrombin gene could be a genetic risk factor for developing myocardial infarction.
KEYWORDS Myocardial infarction; Risk factors; Prothrombin; DNA polymorphism
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F Burzotta, K Paciaroni, V De Stefano, F Crea, A Maseri, G Leone, and F Andreotti G20210A Prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12 034 subjects Heart, January 1, 2004; 90(1): 82 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Mannucci, D. Ardissino, P. A. Merlini, F. Peyvandi, Y.-G. Xie, C. Butt, and E. Randell Vagaries of genetic association studies in myocardial infarction Blood, August 15, 2003; 102(4): 1558 - 1560. [Full Text] [PDF]
|
|
|
|
|
|
C. Butt, H. Zheng, E. Randell, D. Robb, P. Parfrey, and Y.-G. Xie Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction Blood, April 15, 2003; 101(8): 3037 - 3041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Burzotta, K. Paciaroni, V. De Stefano, P. Chiusolo, A. Manzoli, I. Casorelli, A.M. Leone, E. Rossi, G. Leone, A. Maseri, et al. Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease Eur. Heart J., January 1, 2002; 23(1): 26 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Boekholdt, N. R. Bijsterveld, A. H.M. Moons, M. Levi, H. R. Buller, and R. J.G. Peters Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction: A Systematic Review Circulation, December 18, 2001; 104(25): 3063 - 3068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington and K. P. Klein Genome and Hormones: Gender Differences in Physiology: Invited Review: Pharmacogenetics of estrogen replacement therapy J Appl Physiol, December 1, 2001; 91(6): 2776 - 2784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mira, J. Todoli, R. Alonso, M. L. Mico, A. Vaya, F. Ferrando, A. Estelles, P. Villa, and J. Aznar Factor V Leiden and Prothrombin G20210A in Relation to Arterial and/or Vein Rethrombosis: Two Cases Clinical and Applied Thrombosis/Hemostasis, July 1, 2001; 7(3): 234 - 237. [Abstract] [PDF]
|
|
|
|
|
|
C. Russo, D. Girelli, O. Olivieri, P. Guarini, F. Manzato, F. Pizzolo, B. Zaia, A. Mazzucco, and R. Corrocher G20210A Prothrombin Gene Polymorphism and Prothrombin Activity in Subjects With or Without Angiographically Documented Coronary Artery Disease Circulation, May 22, 2001; 103(20): 2436 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Psaty, N. L. Smith, R. N. Lemaitre, H. L. Vos, S. R. Heckbert, A. Z. LaCroix, and F. R. Rosendaal Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Myocardial Infarction in Postmenopausal Women JAMA, February 21, 2001; 285(7): 906 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vaya, R. Trenor, S. Molla, A. Estelles, Y. Mira, P. Villa, and J. Aznar Acute Myocardial Infarction Associated With the Prothrombin G20210A Mutation Clinical and Applied Thrombosis/Hemostasis, April 1, 2000; 6(2): 111 - 112. [PDF]
|
|
|
|
 |
|
 R. D. Rosenberg and W. C. Aird Vascular-Bed-Specific Hemostasis and Hypercoagulable States N. Engl. J. Med., May 20, 1999; 340(20): 1555 - 1564. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Redondo, H. H. Watzke, B. Stucki, I. Sulzer, F. D. Biasiutti, B. R. Binder, M. Furlan, B. Lammle, and W. A. Wuillemin Coagulation Factors II, V, VII, and X, Prothrombin Gene 20210G->A Transition, and Factor V Leiden in Coronary Artery Disease : High Factor V Clotting Activity Is an Independent Risk Factor for Myocardial Infarction Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 1020 - 1025. [Abstract] [Full Text] [PDF]
|
|